Seth Klarman
Baupost Group
Seth Klarman Takeda Pharmaceutical Co Ltd ADR stake
total: 272
Baupost Group TAK trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 2
- Held since:
- 2019 Q1
- Held for:
- 3 quarters
- Latest activity:
- 2019 Q4
According to 2026 Q2 report, Seth Klarman doesn't hold any Takeda Pharmaceutical Co Ltd ADR (TAK) shares. To date, the estimated cost basis is nearly $20.37 for "buy" trades and estimated average "sell" price is $17.26. Baupost Group first purchased TAK in 2019 Q1, initially acquiring about 10.67M shares. Since the initial investment in Takeda Pharmaceutical Co Ltd ADR (TAK), Baupost Group has made 3 more transactions.
When did Seth Klarman sell Takeda Pharmaceutical Co Ltd ADR (TAK)?
Seth Klarman sold off the entire Takeda Pharmaceutical Co Ltd ADR (TAK) position in 2019 Q4.
When did Seth Klarman buy Takeda Pharmaceutical Co Ltd ADR (TAK)?
Seth Klarman first invested in Takeda Pharmaceutical Co Ltd ADR (TAK) in 2019 Q1 at the reported quarter-end price of $20.37 per share.
What's the cost basis of Baupost Group's TAK stake?
The estimated cost basis for Takeda Pharmaceutical Co Ltd ADR (TAK) stake is around $20.37 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $20.37
- Weighted AVG sell price:
- $17.26
Seth Klarman's historical trades in Takeda Pharmaceutical Co Ltd ADR
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2019 Q4
|
0.00%
|
$17.20
|
-100% (-9,434,803)
|
|||
|
2019 Q3
|
1.84%
|
$17.20
|
-0.03% (-3,200)
|
|||
|
2019 Q2
|
1.51%
|
$17.70
|
-11.54% (-1,231,018)
|
|||
|
2019 Q1
|
1.83%
|
$20.37
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.